Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders.
Anorexia nervosa
Binge eating disorder
Bulimia nervosa
Complementary therapy
Eating disorder
Pharmacotherapy
Psychedelics
Treatment
Journal
Journal of integrative neuroscience
ISSN: 0219-6352
Titre abrégé: J Integr Neurosci
Pays: Singapore
ID NLM: 101156357
Informations de publication
Date de publication:
30 Sep 2021
30 Sep 2021
Historique:
received:
22
02
2021
revised:
09
03
2021
accepted:
19
04
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
1
2
2022
Statut:
ppublish
Résumé
Approximately 1.25 million people in the UK suffer from an eating disorder, yet the treatment options show limited efficacy, warranting the need for novel approaches. This study aimed to investigate the perspectives of people with eating disorders on the use of complementary therapies and psychedelic research and treatment. Two hundred participants with eating disorders took part in this web survey study. The majority of participants (70%) had used a complementary treatment to manage their eating disorder. Participants believed that psychedelic research was worthwhile in the context of a moderate level of concern. The most popular solutions to meet these concerns included providing education around psychedelics and their effects and use in psychiatry and experiencing endorsement from professionals in the area. Moreover, participant responses emphasized the need for a safe, monitored environment and the patient-therapist rapport in the context of psychedelic treatment. The findings are explored concerning future trials of psychedelics as a treatment for eating disorders.
Identifiants
pubmed: 34645088
pii: 1632962191325-1116268835
doi: 10.31083/j.jin2003059
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-560Informations de copyright
© 2021 The Author(s). Published by IMR Press.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.